反应详情

This was prepared using, the same procedure as for 4-(6-bromo-2-(4-(dimethylamino)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)-N-phenylpiperazine-1-carboxamide, but here using 2-(4-(2-amino-5-bromo-3-nitropyridin-4-yl)piperazin-1-yl)-N-(thiazol-2-yl)acetamide (50 mg, 0.11 mmol), DMF (1 mL), 1M Na2S2O4 (3 eq, 0.33 mmol, 0.33 mL) and 3-pyridinecarboxaldehyde (1.05 eq, 0.12 mmol, 0.011 mL). After 16 h, the DMF was removed in vacuo, the residue taken up in water (2 mL) and extracted with EtOAc (2×3 mL) and CH2Cl2 (2×3 mL). The combined extracts were dried (Na2SO4) and concentrated in vacuo to give the product (21 mg, 38%) as a pale brown solid; 1H-NMR (500 MHz, DMSO-d6) 3.30 (hidden by water-in-DMSO peak, 6H, NCH2CO and piperazine N(CH2)2), 3.89 (br s, 4H, piperazine N(CH2)2), 7.28 (br s, 1H, thiazole H-4 or H-5), 7.52 (d, J=3.5 Hz, 1H, thiazole H-4 or H-5), 7.60 (dd, J=7.9, 4.8 Hz, 1H, pyridine H-5), 8.32 (s, 1H, imidazo[4,5-b]pyridine H-5), 8.52 (d, br, J=8.0 Hz, 1H, pyridine H-4), 8.71 (d, br, J=4.7 Hz, 1H, pyridine H-6), 9.38 (s, 1H, pyridine H-2), 13.80 (s, br, 1H, imidazo[4,5-b]pyridine NH);

1. customThis was prepared
2. customthe DMF was removed in vacuo
3. extractionextracted with EtOAc (2×3 mL) and CH2Cl2 (2×3 mL)
4. dry with materialThe combined extracts were dried (Na2SO4)
5. concentrationconcentrated in vacuo